Danske Bank downgraded Xvivo Perfusion (XVIPF) to Sell from Buy with a price target of SEK 325, down from SEK 560. The firm sees short-term headwinds and a “too rich” valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XVIPF: